Phosphate ion

Researchers discovered a synthetic antioxidant, MDP, inspired by *Deinococcus radiodurans*, offering protection against radiation. This breakthrough could lead to new radiation protection methods, vaccines, and treatments for radiation illnesses, with potential applications in space exploration and clinical diagnostics.

Unicycive Therapeutics announced bioequivalence of Oxylanthanum Carbonate (OLC) to Fosrenol®, with data published in Clinical Therapeutics. OLC, a phosphate binder for hyperphosphatemia in kidney disease, showed similar efficacy and tolerability to lanthanum carbonate in a study with 75 participants. Unicycive is preparing for OLC's 2025 commercial launch, pending FDA approval.

Unicycive Therapeutics announced bioequivalence of oxylanthanum carbonate (OLC) to Fosrenol® in a study published in Clinical Therapeutics. OLC, a phosphate binder for hyperphosphatemia in kidney disease, showed similar efficacy and tolerability to lanthanum carbonate. Unicycive is preparing for OLC's commercial launch in 2025, pending FDA approval.

Unicycive Therapeutics announced the publication of its oxylanthanum carbonate (OLC) bioequivalence study in Clinical Therapeutics, showing OLC's equivalence to Fosrenol® in healthy volunteers. OLC, a next-gen phosphate binder, is under FDA review with a potential 2025 launch. It aims to treat hyperphosphatemia in CKD patients, offering lower pill burden and better compliance.